This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
CCDC106 / Coiled-coil domain-containing protein 106 · Western blot design guide
Design a Western Blot for CCDC106
Source-linked CCDC106 Western blot protocol options, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-CCDC106 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled October 2026 · For research use; verify linked source records and product datasheet before use
CCDC106 Western Blot Experimental Design Guide
Expected bands, source-linked protocol options, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~32 kDa | |
| Observed band | 68 kDa | |
| Gel | 12–15% (standard starting point) | |
| Negative control | Suggested KO / knockdown lysate |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | Phosphorylated | |
| Caveat | Band identity controls | |
| Gene-set association | MSigDB Hallmark membership | |
| Isoform | 1 isoform(s) |
Section 1
Source-Linked CCDC106 Western Blot Protocol Options
The A15044-1 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | human brain tissue lysate (catalog A15044-1) |
| Gel % | 12–15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Standard semi-dry transfer; verify efficiency (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | A15044-1 · (A) 0.5 and (B) 1 μg/mL (catalog A15044-1) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
Section 2
What Is the Expected CCDC106 Western Blot Band Size?
CCDC106 is predicted at 32 kDa, while the empirical antibody band is 68 kDa; the cause of the difference is not established.
| Band near 68 kDa | Matches the empirical antibody band; confirm CCDC106 identity by depletion or an independent antibody |
| Band near 32 kDa | Matches the predicted sequence mass, but identity requires validation |
| Stronger band in a nuclear fraction | Consistent with the reported nuclear location |
| Possible doublet | Ser130 phosphorylation is documented, but a visible shift has not been established |
💡Expected CCDC106 appearanceCCDC106 is predicted to weigh 32 kDa, while an antibody QC blot reports a band at 68 kDa; the cause of the difference is unknown, so confirm band identity with depletion or an independent antibody.
| Predicted molecular mass | The UniProt sequence gives a mass of approximately 32 kDa |
| Exact sequence mass | 32,032 Da corresponds to approximately 32 kDa |
| Full-length mass prediction | The 32 kDa estimate applies to the 280-residue sequence |
| Predicted mass versus empirical migration | The 32 kDa sequence prediction does not explain the observed 68 kDa band |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | Nuclear CCDC106 may be poorly recovered | Check nuclear protein recovery and compare a nuclear fraction |
| Band higher than expected | The empirical 68 kDa band exceeds the predicted 32 kDa mass for an unknown reason | Confirm its identity by CCDC106 depletion or an independent antibody |
| Band lower than expected | The identity of a smaller band is unestablished | Check whether it disappears after CCDC106 depletion |
| Multiple bands | Ser130 phosphorylation is documented, but separate migrating bands are unproven | Test band identity by depletion and assess phosphatase sensitivity if relevant |
| Weak or no signal | Nuclear CCDC106 may be poorly recovered | Check extraction and antibody performance with a positive control |
| Broad smear instead of sharp band | No supplied CCDC106 feature establishes a smear | Compare with CCDC106-depleted material and check sample quality |
Experiment evidence
Western blot images showing CCDC106 band
A15044-1 · CCDC106
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for CCDC106 Western blot
🧪For positive controls for CCDC106 in Western blot, you can use a validated CCDC106-expressing sample, since the supplied HPA evidence identifies no positive tissue or cell line.
Positive control: No high/medium HPA tissue identified
Negative control: Suggested KO / knockdown lysate
Loading controls: Run GAPDH, β-actin, and a total-protein stain alongside the samples.
⚠️Feasibility: HPA has no tissue data, so sample controls require validation; a knockdown or KO line can provide a negative control.
HPA tissue expression evidence for CCDC106
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No high/medium HPA tissues identified in the supplied evidence. | ||||
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No lower-expression tissue rows available in the supplied evidence. | ||||
Section 3
Advanced CCDC106 Western Blot Tips
Deeper troubleshooting and optimisation questions for CCDC106, answered from its protein features.
How should CCDC106 band migration be interpreted?
Band shift · Use the separately labelled calculated mass and catalog-observed evidence above. A sequence annotation does not establish an observed migration shift. Verify target identity with orthogonal controls.
Could an isoform explain the 68 kDa band?
Isoforms · The supplied record lists one isoform and no alternative sequence. It provides no isoform-based explanation for the 68 kDa band.
Does phosphorylation change the expected CCDC106 band?
PTM · UniProt lists phosphoserine at position 130 in its sequence numbering. This establishes a modification site, but does not show that phosphorylation causes a visible shift or accounts for the 68 kDa band.
Does this guide establish induction of CCDC106?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
What transfer method to use for CCDC106 Western blot?
Transfer · The features do not specify a transfer method. Because the predicted mass is 32 kDa and the reported band is 68 kDa, check transfer at both positions with a molecular-weight marker when assessing the signal.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the A15044-1 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should CCDC106 signal be quantified?
Quantitation · CCDC106 is reported in the nucleus. Compare samples prepared the same way and normalize to a suitable loading measure for the fraction analyzed; keep the band assignment consistent across samples.
Why does CCDC106 appear at 68 kDa instead of 32 kDa?
Interpretation · UniProt predicts 32 kDa, while the reported band is 68 kDa. The supplied features do not establish the cause. Confirm band identity before assigning the 68 kDa signal to CCDC106; its phosphoserine site and p53 interaction alone do not explain the difference.
Compare each band with the 32 kDa predicted mass and the reported 68 kDa band, then verify its identity. CCDC106 interacts with p53, but that interaction alone does not identify an unexpected band or establish that it is a complex.
Compare each band with the 32 kDa predicted mass and the reported 68 kDa band, then verify its identity. CCDC106 interacts with p53, but that interaction alone does not identify an unexpected band or establish that it is a complex.
Boster reagents
CCDC106 Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-CCDC106 Antibody
Cat # A15044-1
the supplier A15044-1 is an anti-CCDC106 antibody listed as reactive with human, mouse, and rat. Its Western blot image uses human brain tissue lysate at 0.5 and 1 μg/mL; the supplied evidence does not show mouse or rat blots.
Which to pick: A15044-1 is the only listed option. Its WB image documents use with human brain tissue lysate; mouse and rat reactivity is listed, but no WB images for those species are supplied.
Source: BosterBio CCDC106 gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry Q9BWC9.
- Human Protein Atlas. CCDC106 tissue expression.
- PMC9796641 — target-verified WB comparison